thyroxine has been researched along with Hypertrophy, Left Ventricular in 16 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On echocardiography, the left ventricular hypertrophy, identified earlier, shoed partial regression." | 1.91 | Heart failure in a cat due to hypertrophic cardiomyopathy phenotype caused by chronic uncontrolled hyperthyroidism. ( Chae, Y; Kang, BT; Kim, H; Koo, Y; Lee, D; Lee, H; Park, J; Yang, MP; Yun, T, 2023) |
| "Pravastatin treatment led to inhibition of Rac-GTPase activity and integrin signaling." | 1.37 | Cardiac remodeling caused by transgenic overexpression of a corn Rac gene. ( Abouelnaga, ZA; Alhaj, MA; Awad, MM; Citro, LA; El-Sayed, O; Elnakish, MT; Hassanain, HH; Hassona, MD; Khan, M; Kulkarni, A; Kuppusamy, P; Moldovan, L; Sayyid, M, 2011) |
| "The ventricular remodeling of mice were induced by subcutaneous injection of ISO with the dosage of 2 mg/kg daily for 7 d and the rats with L-Thy intraperitoneally with the dosage of 0." | 1.36 | [Effect of Chrysanthemum indicum on ventricular remodeling in rats]. ( Chen, CX; Gao, JP; Gu, WL; Lv, J; Wan, Y; Wu, Q, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, H | 1 |
| Lee, D | 1 |
| Park, J | 1 |
| Yun, T | 1 |
| Koo, Y | 1 |
| Chae, Y | 1 |
| Kang, BT | 1 |
| Yang, MP | 1 |
| Kim, H | 1 |
| Badi, R | 1 |
| Teixeira, RB | 1 |
| Zimmer, A | 1 |
| de Castro, AL | 1 |
| Carraro, CC | 1 |
| Casali, KR | 1 |
| Dias, IGM | 1 |
| Godoy, AEG | 1 |
| Litvin, IE | 1 |
| Belló-Klein, A | 1 |
| da Rosa Araujo, AS | 1 |
| Karavelioglu, Y | 1 |
| Baran, A | 1 |
| Karapinar, H | 1 |
| Küçükdurmaz, Z | 1 |
| Yilmaz, A | 1 |
| Wu, Q | 1 |
| Chen, CX | 1 |
| Gu, WL | 1 |
| Gao, JP | 1 |
| Wan, Y | 1 |
| Lv, J | 1 |
| Elnakish, MT | 1 |
| Awad, MM | 1 |
| Hassona, MD | 1 |
| Alhaj, MA | 1 |
| Kulkarni, A | 1 |
| Citro, LA | 1 |
| Sayyid, M | 1 |
| Abouelnaga, ZA | 1 |
| El-Sayed, O | 1 |
| Kuppusamy, P | 1 |
| Moldovan, L | 1 |
| Khan, M | 1 |
| Hassanain, HH | 1 |
| Matuszewska, G | 1 |
| Roskosz, J | 1 |
| Włoch, J | 1 |
| Jurecka-Tuleja, B | 1 |
| Hasse-Lazar, K | 1 |
| Kowalczyk, P | 1 |
| Jarzab, B | 1 |
| Mark, PB | 1 |
| Watkins, S | 1 |
| Dargie, HJ | 1 |
| Fernandes, ML | 1 |
| Ferro, EA | 1 |
| Beletti, ME | 1 |
| Resende, ES | 1 |
| Song, LJ | 1 |
| Wang, GL | 1 |
| Liu, J | 1 |
| Qiu, QY | 1 |
| Ou, JH | 1 |
| Guan, YY | 1 |
| Robert, V | 1 |
| Silvestre, JS | 1 |
| Charlemagne, D | 1 |
| Sabri, A | 1 |
| Trouvé, P | 1 |
| Wassef, M | 1 |
| Swynghedauw, B | 2 |
| Delcayre, C | 1 |
| Biondi, B | 1 |
| Fazio, S | 1 |
| Carella, C | 1 |
| Amato, G | 1 |
| Cittadini, A | 1 |
| Lupoli, G | 1 |
| Saccà, L | 1 |
| Bellastella, A | 1 |
| Lombardi, G | 1 |
| Moalic, JM | 1 |
| Bourgeois, F | 1 |
| Mansier, P | 1 |
| Machida, CA | 1 |
| Carré, F | 1 |
| Chevalier, B | 1 |
| Pitarque, P | 1 |
| Tomanek, RJ | 2 |
| Butters, CA | 1 |
| Zimmerman, MB | 1 |
| Chang, KC | 1 |
| Figueredo, VM | 1 |
| Schreur, JH | 1 |
| Kariya, K | 1 |
| Weiner, MW | 1 |
| Simpson, PC | 1 |
| Camacho, SA | 1 |
| Doty, MK | 1 |
| Sandra, A | 1 |
1 trial available for thyroxine and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
[Evaluation of effects of L-thyroxine therapy in differentiated thyroid carcinoma on the cardiovascular system --prospective study].
Topics: Female; Humans; Hypertrophy, Left Ventricular; Iodine Radioisotopes; Male; Middle Aged; Prospective | 2001 |
15 other studies available for thyroxine and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Heart failure in a cat due to hypertrophic cardiomyopathy phenotype caused by chronic uncontrolled hyperthyroidism.
Topics: Animals; Cardiomegaly; Cardiomyopathy, Hypertrophic; Cat Diseases; Cats; Furosemide; Heart Failure; | 2023 |
Acylated Ghrelin Attenuates l-Thyroxin-induced Cardiac Damage in Rats by Antioxidant and Anti-inflammatory Effects and Downregulating Components of the Cardiac Renin-angiotensin System.
Topics: Acylation; Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Ghrelin; Hyperth | 2021 |
Exercise training versus T3 and T4 hormones treatment: The differential benefits of thyroid hormones on the parasympathetic drive of infarcted rats.
Topics: Animals; Echocardiography; Exercise Therapy; Fibrosis; Hypertrophy, Left Ventricular; Male; Myocardi | 2018 |
Reversible cardiomyopathy associated with autoimmune polyendocrine syndrome type II.
Topics: Adult; Cardiomyopathies; Delayed Diagnosis; Female; Fludrocortisone; Hormone Replacement Therapy; Hu | 2013 |
[Effect of Chrysanthemum indicum on ventricular remodeling in rats].
Topics: Aldosterone; Angiotensin II; Animals; Chrysanthemum; Disease Models, Animal; Drugs, Chinese Herbal; | 2010 |
Cardiac remodeling caused by transgenic overexpression of a corn Rac gene.
Topics: Aging; Amino Acid Sequence; Analysis of Variance; Animals; Echocardiography; Genotype; Hypertrophy, | 2011 |
Cardiomyopathy induced by performance enhancing drugs in a competitive bodybuilder.
Topics: Adult; Anabolic Agents; Doping in Sports; Ephedrine; Growth Hormone; Humans; Hypertrophy, Left Ventr | 2005 |
Spironolactone effects on myocardium changes induced by thyroid hormone in rats.
Topics: Analysis of Variance; Animals; Body Weight; Heart; Heart Rate; Hypertrophy, Left Ventricular; Male; | 2007 |
Cellular mechanisms of reduced sarcoplasmic reticulum Ca2+ content in L-thyroxin induced rat ventricular hypertrophy.
Topics: Animals; Caffeine; Calcium; Cardiomegaly; Electrocardiography; Heart Ventricles; Hypertrophy, Left V | 2008 |
Biological determinants of aldosterone-induced cardiac fibrosis in rats.
Topics: Aldosterone; Animals; Blotting, Northern; Collagen; Fibrosis; Heart; Histocytochemistry; Hypertensio | 1995 |
Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine.
Topics: Adult; Arrhythmias, Cardiac; Blood Pressure; Cardiomegaly; Echocardiography; Electrocardiography; El | 1993 |
Beta 1 adrenergic receptor and G alpha s mRNAs in rat heart as a function of mechanical load and thyroxine intoxication.
Topics: Animals; Blotting, Northern; GTP-Binding Proteins; Hypertrophy, Left Ventricular; Male; Myocardium; | 1993 |
Initiation of cardiac hypertrophy in response to thyroxine is not limited by age.
Topics: Aging; Animals; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Heart; Hemodynamics; | 1993 |
Thyroid hormone improves function and Ca2+ handling in pressure overload hypertrophy. Association with increased sarcoplasmic reticulum Ca2+-ATPase and alpha-myosin heavy chain in rat hearts.
Topics: Animals; Aorta; Aortic Valve Stenosis; Calcium; Calcium-Binding Proteins; Calcium-Transporting ATPas | 1997 |
Early coronary angiogenesis in response to thyroxine: growth characteristics and upregulation of basic fibroblast growth factor.
Topics: Animals; Capillaries; Coronary Vessels; Fibroblast Growth Factor 2; Gene Expression; Hypertrophy, Le | 1998 |